Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update

Gordan et al. (Tue,) studied this question.

www.synapsesocial.com/papers/68e734edb6db6435876ae275 — DOI: https://doi.org/10.1200/jco.23.02745

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States· 2010 · 248 citations
2. American Society of Clinical Oncology Position Statement: Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority Populations· 2017 · 253 citations
3. Drug Costs vs Probability of Survival in Lung Cancer: Impact of Dosage, Duration, and Immune Checkpoint Inhibitor Combinations· 2019 · 3 citations
4. Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma· 2023 · 30 citations
5. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study· 2022 · 227 citations